StreetInsider.com News Articles

H.C. Wainwright Reiterates Buy Rating on Microbot Medical (MBOT)

Wed, 21 Oct 2026 06:52:49 -0400

H.C. Wainwright analyst Raghuram Selvaraju reiterated a Buy rating and $12.00 price target on Microbot Medical (NASDAQ: MBOT).

The analyst commented: "Global patent portfolio expands alongside LIBERTY’s commercial rollout. Yesterday, Microbot Medical announced new patent approvals in the U.S., Japan, China and Canada, bringing its global portfolio to 44 issued patents and 49 pending patent applications. In our view, the broader patent portfolio supports protection of LIBERTY, the company’s FDA-cleared, single-use, remotely operated robotic system for peripheral endovascular procedures, as the company expands its commercial reach. The update follows a three-year exclusive distribution agreement with Medtechnica in Israel, with initial orders

Microbot Medical receives new patents in U.S., Japan, China, Canada

Tue, 20 Oct 2026 08:33:07 -0400

Microbot Medical Inc. (NASDAQ: MBOT) has received several new patent approvals across the United States, Japan, China, and Canada, bringing its total to 44 issued patents and 49 pending patent applications globally, according to a company statement.

The patents cover technology related to the company's LIBERTY Endovascular Robotic System, a single-use robotic device cleared by the U.S. Food and Drug Administration for peripheral endovascular procedures. The company's patent portfolio spans North America, Europe, Israel, and Asia.

"Our R&D and Business Development teams' ongoing collaboration is resulting in a robust and diverse intellectual property portfolio, which we expect to expand significantly over the

Form 8-K Microbot Medical Inc. For: Oct 14

Tue, 20 Oct 2026 08:30:00 -0400

si-local-file:///var/storage/secattach/20261020/27207239.html

Microbot Medical® Granted Multiple New Patents, Further Strengthening Its Global Intellectual Property Portfolio

Tue, 20 Oct 2026 08:30:00 -0400

The Company now holds 44 issued patents and 49 pending patents globally. Commercialization continues to advance across both U.S. and international markets.

HINGHAM, Mass., Oct. 20, 2026 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer and distributor of the innovative LIBERTY® Endovascular Robotic System, announced that it has received several new patent approvals across the U.S., Japan, China and Canada, further strengthening its global intellectual property portfolio as the Company continues to expand commercial adoption of the LIBERTY® System in the U.S. and position it for growth in key international markets as

Microbot Medical® Granted Multiple New Patents, Further Strengthening Its Global Intellectual Property Portfolio

Tue, 20 Oct 2026 08:30:00 -0400

The Company now holds 44 issued patents and 49 pending patents globally. Commercialization continues to advance across both U.S. and international markets.

Microbot Medical signs 3-year Israel distribution deal with Medtechnica

Tue, 06 Oct 2026 08:31:53 -0400

Microbot Medical Inc. (NASDAQ: MBOT) has signed a three-year exclusive distribution agreement with Medtechnica Ltd. to market and sell its Liberty Endovascular Robotic System in Israel, according to a press release statement.

Microbot Medical received regulatory approval from the Israeli Ministry of Health's AMAR Division and was registered in the Israeli Medical Device Registry in May 2026. The company said it anticipates initial orders from Medtechnica Ltd. during the fourth quarter of 2026.

Harel Gadot, CEO, President and Chairman of Microbot Medical, said the agreement is "an important milestone" and expressed expectations that hospitals and physicians in Israel will gain access to

Microbot Medical® and Medtechnica Ltd. Enter into Three-Year Exclusive Distribution Agreement in Israel

Tue, 06 Oct 2026 08:30:00 -0400

Medtechnica Ltd., a Leading Medical Device Distributor in Israel, Authorized to Distribute the LIBERTY^® Endovascular Robotic System Throughout Israel

Microbot Medical is Executing its International Markets Strategy by Engaging with Distributors in Developed Markets to Prepare for Potential Future Market Entry Outside of the U.S.

HINGHAM, Mass., Oct. 06, 2026 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer and distributor of the innovative LIBERTY^® Endovascular Robotic System, announced that it has signed a three-year exclusive commercial distribution agreement with Medtechnica Ltd. to market and sell the Company's LIBERTY System in Israel. The Company

Microbot Medical® and Medtechnica Ltd. Enter into Three-Year Exclusive Distribution Agreement in Israel

Tue, 06 Oct 2026 08:30:00 -0400

Form 8-K Microbot Medical Inc. For: Oct 06

Tue, 06 Oct 2026 08:30:00 -0400

si-local-file:///var/storage/secattach/20261006/27152538.html

Form 8-K Microbot Medical Inc. For: Sep 25

Mon, 28 Sep 2026 06:25:00 -0400

si-local-file:///var/storage/secattach/20260928/27109709.html

Microbot Medical® Highlights Growth Strategy

Fri, 25 Sep 2026 17:30:00 -0400

User Survey Demonstrates High Satisfaction of the LIBERTY System

Expansion of Sales Footprint Expands to Western U.S. as Company Secures First California Customer

HINGHAM, Mass., Sept. 25, 2026 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), announced that it highlighted the continuation of its commercial and growth strategy during an analyst meeting held in New York City on Thursday, September 24, 2026. The Company also highlighted select results from a user survey, available on the Company’s website, conveying high satisfaction with the system.

Key Topics Discussed:

Expansion of

Microbot Medical® Highlights Growth Strategy

Fri, 25 Sep 2026 17:30:00 -0400

User Survey Demonstrates High Satisfaction of the LIBERTY System

Expansion of Sales Footprint Expands to Western U.S. as Company Secures First California Customer

Key Topics Discussed:

Expansion of

H.C. Wainwright Reiterates Buy Rating on Microbot Medical (MBOT)

Wed, 19 Aug 2026 06:48:19 -0400

H.C. Wainwright analyst Raghuram Selvaraju reiterated a Buy rating and $12.00 price target on Microbot Medical (NASDAQ: MBOT).

The analyst commented: "Microbot Medical recently reported its 2Q26 financial results. Revenue was $241K, representing over 100% QoQ growth and beating our projection of $220K. Net loss was $5.6M, or ($0.08) per share, more than our estimated loss of $4.0M. Of note, the company commenced the full market release of the LIBERTY System in April 2026. Following Georgia, Florida, and New York, new health systems in Massachusetts, North Carolina, Michigan, and Pennsylvania have adopted the LIBERTY System, with an increasing number of hospital

Microbot Medical (MBOT) PT Lowered to $4 at B.Riley

Fri, 14 Aug 2026 08:29:34 -0400

B.Riley analyst Anderson Schock lowered the price target on Microbot Medical (NASDAQ: MBOT) to $4.00 (from $5.00) while maintaining a Buy rating.

Form 8-K Microbot Medical Inc. For: Aug 11

Tue, 11 Aug 2026 10:28:00 -0400

si-local-file:///var/storage/secattach/20260811/26903434.html

Form 8-K Microbot Medical Inc. For: Aug 11

Tue, 11 Aug 2026 10:28:00 -0400

si-local-file:///var/storage/secattach/20260811/26903434.html

Microbot Medical revenue more than doubles in Q2 2026

Tue, 11 Aug 2026 09:20:33 -0400

Microbot Medical Inc. (NASDAQ: MBOT) reported revenue growth of more than 100% in its fiscal second quarter ended June 30, 2026, compared to the first quarter ended March 31, 2026, according to a 10-Q filing with the Securities and Exchange Commission.

The company attributed the increase to repeat orders, expanded utilization among existing customers, and new customer additions following the Full Market Release of its LIBERTY Endovascular Robotic System in mid-April 2026. The Full Market Release was launched at the Society of Interventional Radiology Annual Scientific Meeting.

New health systems in Massachusetts, North Carolina, Michigan, and Pennsylvania adopted the LIBERTY System during

Microbot Medical® Files 10-Q, Reports Significant Revenue and Customer Growth During the 2026 Second Quarter

Tue, 11 Aug 2026 09:20:00 -0400

Revenue increased by more than 100% over the prior fiscal quarter, driven by repeat orders, expanded utilization among existing customers, and the acquisition of new customers since the Full Market Release in mid-April

The Company added new customers in Q3 while expanding into new states and sites of service

HINGHAM, Mass., Aug. 11, 2026 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer and distributor of the innovative LIBERTY® Endovascular Robotic System, announced that it has filed its Quarterly Report on Form 10-Q for the fiscal quarter ended June

Microbot Medical® Files 10-Q, Reports Significant Revenue and Customer Growth During the 2026 Second Quarter

Tue, 11 Aug 2026 09:20:00 -0400

The Company added new customers in Q3 while expanding into new states and sites of service

Microbot Medical® Files 10-Q, Reports Significant Revenue and Customer Growth During the 2026 Second Quarter

Tue, 11 Aug 2026 09:20:00 -0400

The Company added new customers in Q3 while expanding into new states and sites of service

Microbot Medical® Files 10-Q, Reports Significant Revenue and Customer Growth During the 2026 Second Quarter

Tue, 11 Aug 2026 09:20:00 -0400

The Company added new customers in Q3 while expanding into new states and sites of service

Form 10-Q Microbot Medical Inc. For: Jun 30

Tue, 11 Aug 2026 09:15:00 -0400

si-local-file:///var/storage/secattach/20260811/26902788.html

Form 10-Q Microbot Medical Inc. For: Jun 30

Tue, 11 Aug 2026 09:15:00 -0400

si-local-file:///var/storage/secattach/20260811/26902788.html

Form 8-K Microbot Medical Inc. For: Aug 06

Fri, 07 Aug 2026 16:31:00 -0400

si-local-file:///var/storage/secattach/20260807/26891566.html

Form 8-K Microbot Medical Inc. For: Aug 06

Fri, 07 Aug 2026 16:31:00 -0400

si-local-file:///var/storage/secattach/20260807/26891566.html